Bispecific anti PD1-anti TIM3 antibodies

Patent metadata

Field	Value
Publication number	US-12577306-B2
Application number	US-202318359660-A
Country	US
Kind code	B2
Filing date	Jul 26, 2023
Priority date	Jul 6, 2017
Publication date	Mar 17, 2026
Grant date	Mar 17, 2026

Abstract

The disclosure provide means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) mediated inhibition in a PD-1 and/or TIM-3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3, thereby inhibiting PD-1 and/or TIM-3 mediated activity in said cell. The invention also provides antibodies or variant thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3.

First claim

The invention claimed is:

1 . A method for interfering with Programmed Cell Death 1 protein (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) mediated inhibition in a PD-1 and/or TIM-3 positive cell, the method comprising contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises
a variable domain that can bind to an extracellular part of PD-1 comprising a heavy chain variable region with a CDR1, CDR2 and CDR3 region that comprises the amino acid sequence of the CDR1, CDR2 and CDR3 of a heavy chain variable region according to any one of MF6076 (SEQ ID NO: 43); MF6226 (SEQ ID NO: 44); MF6236 (SEQ ID NO: 45); MF6256 (SEQ ID NO: 46); MF6930 (SEQ ID NO: 47); MF6932 (SEQ ID NO: 48); MF6935 (SEQ ID NO: 49); MF6936 (SEQ ID NO: 50); MF6972 (SEQ ID NO: 51); MF6974 (SEQ ID NO: 52); or MF6982 (SEQ ID NO: 53); and a variable domain that can bind to an extracellular part of TIM-3 comprising a heavy chain variable region with a CDR1, CDR2 and CDR3 region that comprises the amino acid sequence of the CDR1, CDR2 and CDR3 of a heavy chain variable region according to any one of MF7676 (SEQ ID NO: 54); MF7677 (SEQ ID NO: 55); MF7678 (SEQ ID NO: 56); or MF7679 (SEQ ID NO: 57); wherein the variable domains that can bind to an extracellular part of PD-1 and TIM-3 comprise a light chain variable region having the CDR1, CDR2 and CDR3 sequences of the light chain variable region according to SEQ ID NO: 26, thereby inhibiting PD-1 and/or TIM-3 mediated activity in said cell.

2 . The method of claim 1 , wherein the binding of said PD-1 binding variable domain to PD-1 blocks the binding of PD-1 to PD-L1 and/or PD-L2.

3 . A method for treating cancer or an infection with a pathogen, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or variant thereof, that comprises
a variable domain that can bind to an extracellular part of PD-1 comprising a heavy chain variable region with a CDR1, CDR2 and CDR3 region that comprises the amino acid sequence of the CDR1, CDR2 and CDR3 of a heavy chain variable region according to any one of MF6076 (SEQ ID NO: 43); MF6226 (SEQ ID NO: 44); MF6236 (SEQ ID NO: 45); MF6256 (SEQ ID NO: 46); MF6930 (SEQ ID NO: 47); MF6932 (SEQ ID NO: 48); MF6935 (SEQ ID NO: 49); MF6936 (SEQ ID NO: 50); MF6972 (SEQ ID NO: 51); MF6974 (SEQ ID NO: 52); or MF6982 (SEQ ID NO: 53); a variable domain that can bind to an extracellular part of TIM-3 comprising a heavy chain variable region with a CDR1, CDR2 and CDR3 region that comprises the amino acid sequence of the CDR1, CDR2 and CDR3 of a heavy chain variable region according to any one of MF7676 (SEQ ID NO: 54); MF7677 (SEQ ID NO: 55); MF7678 (SEQ ID NO: 56); or MF7679 (SEQ ID NO: 57); and wherein the variable domains that can bind to an extracellular part of PD-1 and TIM-3 comprise a light chain variable region having the CDR1, CDR2 and CDR3 sequences of the light chain variable region according to SEQ ID NO: 26.

4 . The method of claim 1 , wherein the variable domain that binds TIM-3, blocks the binding of TIM-3 to Galectin-9.

5 . The method of claim 1 , wherein the variable domain that binds an extracellular part of PD-1 is defined as a variable region that when in a bivalent monospecific antibody that comprises two of said variable domains that bind PD-1, inhibits PD-1/PD-L1 inhibition in a Jurkat cell in a range of 20-150% when compared to the inhibition obtained with the antibody Nivolumab on a Jurkat cell.

6 . The method of claim 1 , wherein said variable domain that can bind to an extracellular part of PD-1 comprises a heavy chain variable region that comprises the amino acid sequence of the heavy chain variable region according to any one of MF6076 (SEQ ID NO: 43); MF6226 (SEQ ID NO: 44); MF6236 (SEQ ID NO: 45); MF6256 (SEQ ID NO: 46); MF6930 (SEQ ID NO: 47); MF6932 (SEQ ID NO: 48); MF6935 (SEQ ID NO: 49); MF6936 (SEQ ID NO: 50); MF6972 (SEQ ID NO: 51); MF6974 (SEQ ID NO: 52); or MF6982 (SEQ ID NO: 53), having at most 15 amino acid substitutions with respect to the amino acid sequence of the indicated heavy chain variable region, wherein said substitutions are not in the CDR1, CDR2 or CDR3 of the heavy chain variable region.

7 . The method of claim 1 , wherein said variable domain that can bind to an extracellular part of PD-1 comprises a heavy chain variable region that comprises the amino acid sequence of the heavy chain variable region according to any one of MF6076 (SEQ ID NO: 43); MF6226 (SEQ ID NO: 44); MF6236 (SEQ ID NO: 45); MF6256 (SEQ ID NO: 46); MF6226 (SEQ ID NO: 44); MF6930 (SEQ ID NO: 47); MF6932 (SEQ ID NO: 48); MF6935 (SEQ ID NO: 49); MF6936 (SEQ ID NO: 50); MF6972 (SEQ ID NO: 51); MF6974 (SEQ ID NO: 52); or MF6982 (SEQ ID NO: 53).

8 . The method of claim 6 , wherein the variable domain that can bind to an extracellular part of TIM-3 comprises a heavy chain variable region that comprises the amino acid sequence of the heavy chain variable region according to any one of MF7676 (SEQ ID NO: 54); MF7677 (SEQ ID NO: 55); MF7678 (SEQ ID NO: 56); or MF7679 (SEQ ID NO: 57), having at most 15 amino acid substitutions with respect to the amino acid sequence of the indicated heavy chain variable region, wherein said substitutions are not in the CDR1, CDR2 or CDR3 of the heavy chain variable region.

9 . The method of claim 7 , wherein the variable domain that can bind to an extracellular part of TIM-3 comprises a heavy chain variable region that comprises the amino acid sequence of the heavy chain variable region according to any one of MF7676 (SEQ ID NO: 54); MF7677 (SEQ ID NO: 55); MF7678 (SEQ ID NO: 56); or MF7679 (SEQ ID NO: 57).

10 . The method of claim 8 , wherein the antibody comprises a light chain variable region having a sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 26, comprising the CDR1, CDR2 or CDR3 sequences of the light chain variable region according to SEQ ID NO: 26.

11 . The method of claim 9 , wherein the antibody comprises a light chain variable region having the amino acid sequence of SEQ ID NO: 26.

12 . The method of claim 3 , wherein the binding of said PD-1 binding variable domain to PD-1 blocks the binding of PD-1 to PD-L1.

13 . The method of claim 3 , wherein the variable domain that binds TIM-3, blocks the binding of TIM-3 to Galectin-9.

14 . The method of claim 3 , wherein said variable domain that can bind to an extracellular part of PD-1 comprises a heavy chain variable region that comprises the amino acid sequence of the heavy chain variable region according to any one of MF6076 (SEQ ID NO: 43); MF6226 (SEQ ID NO: 44); MF6236 (SEQ ID NO: 45); MF6256 (SEQ ID NO: 46); MF6930 (SEQ ID NO: 47); MF6932 (SEQ ID NO: 48); MF6935 (SEQ ID NO: 49); MF6936 (SEQ ID NO: 50); MF6972 (SEQ ID NO: 51); MF6974 (SEQ ID NO: 52); or MF6982 (SEQ ID NO: 53), having at most 15 amino acid substitutions with respect to the amino acid sequence of the indicated heavy chain variable region, wherein said substitutions are not in the CDR1, CDR2 or CDR3 of the heavy chain variable region.

15 . The method of claim 3 , wherein said variable domain that can bind to an extracellular part of PD-1 comprises a heavy chain variable region that comprises the amino acid sequence of the heavy chain variable region according to any one of MF6076 (SEQ ID NO: 43); MF6226 (SEQ ID NO: 44); MF6236 (SEQ ID NO: 45); MF6256 (SEQ ID NO: 46); MF6930 (SEQ ID NO: 47); MF6932 (SEQ ID NO: 48); MF6935 (SEQ ID NO: 49); MF6936 (SEQ ID NO: 50); MF6972 (SEQ ID NO: 51); MF6974 (SEQ ID NO: 52); or MF6982 (SEQ ID NO: 53).

Assignees

• Merus Nv
• Merus B V

Inventors

• Geuijen Cecilia Anna Wilhelmina
• Klooster Rinse
• De Kruif Cornelis Adriaan
• Tacken Paulus Johannes
• Throsby Mark
• Logtenberg Ton

Classifications

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title

• C07K2317/31

  multispecific · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title